The Teams We Back
Axon Therapies is a clinical stage company developing an interventional therapy to treat heart failure, focused initially on the difficult to treat heart failure with preserved ejection fraction.
Cala Health is developing non-invasive wearable neuromodulation therapies, based on recent neuroscience discoveries. The company’s first FDA cleared indication is for the treatment of essential tremor symptoms.
CVRx has developed BAROSTIM NEO, the world’s first FDA approved neuromodulation therapy for the treatment of heart failure symptoms.
Exo Imaging is delivering high-performance point-of-care handheld imaging on a proprietary ultrasound-chip platform. Their AI-enabled system aims to globally democratize the access to, and use of diagnostic and therapeutic ultrasound.
NeuSpera Medical is a clinical stage company developing minimally invasive neuromodulation therapies using its proprietary MidField Powering technology. The company’s first target-indication is for the treatment of urinary urge incontinence, a symptom of overactive bladder.
Presidio Medical is a clinical-stage company developing a novel platform neuromodulation technology to establish a new class of therapeutic medical devices. The company’s initial focus is on treating chronic pain.
Saluda Medical is dedicated to improving patients’ lives by providing personalized and responsive neuromodulation therapy. The company has developed Evoke®, the first and only Closed-Loop Spinal Cord Stimulation (SCS) System designed to optimize pain relief by measuring and recording each patient’s unique response to stimulation, and then making millions of real-time adjustments per day to maintain a consistent level of therapy.
SetPoint Medical is a clinical stage company developing a novel and potentially transformative approach to treating autoimmune diseases, such as rheumatoid arthritis and inflammatory bowel disease, by using miniaturized implantable devices that regulate the body’s inflammatory reflex.